Phase Ia/Ib trial on the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).
Latest U.S. sanction represents fifth for antibody against hematologic cancers. Genentech and Biogen Idec reported receiving an FDA go-ahead for Rituxan® in combination with fludarabine and ...
An exploratory feasibility study examining the addition of arsenic trioxide (ATO) and ascorbic acid (AA) to bortezomib, thalidomide, and dexamethasone (VTD) in the treatment of relapsed and refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results